Polyphasic Identification and Susceptibility to Seven Antifungals of 102 Aspergillus Isolates Recovered from Immunocompromised Hosts in Greece
AuthorArabatzis, M.; Kambouris, M.; Kyprianou, M.; Chrysaki, A.; Foustoukou, M.; Kanellopoulou, M.; Kondyli, L.; Kouppari, G.; Koutsia-Karouzou, C.; Lebessi, E.; Pangalis, A.; Petinaki, E.; Stathi, A.; Trikka-Graphakos, E.; Vartzioti, E.; Vogiatzi, A.; Vyzantiadis, T. A.; Zerva, L.; Velegraki, A.
In this study, the first such study in Greece, we used polyphasic identification combined with antifungal susceptibility study to analyze Aspergillus clinical isolates comprising 102 common and rare members of sections Fumigati, Flavi, Terrei, Nidulantes, Nigri, Circumdati, Versicolores, and Usti. High amphotericin B MICs (>2 mu g/ml) were found for 17.6% of strains. Itraconazole, posaconazole, and voriconazole MICs of >4 mu g/ml were shown in 1%, 5%, and 0% of the isolates, respectively. Anidulafungin, micafungin, and caspofungin minimum effective concentrations (MECs) of >= 2 mu g/ml were correspondingly recorded for 4%, 9%, and 33%, respectively, of the strains.